Lysyl oxidase-like 2 promotes the survival, migration, and ferroptosis of endometrial cancer cells by activating the phosphoinositide 3-kinase/protein kinase B pathway | ||
| Iranian Journal of Basic Medical Sciences | ||
| مقاله 9، دوره 28، شماره 1، فروردین 2025، صفحه 72-79 اصل مقاله (398 K) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.22038/ijbms.2024.79933.17317 | ||
| نویسندگان | ||
| Jiashi Gu؛ Huanmei Sun؛ Juan Shao؛ Hu Zhang؛ Zhanpeng Zhu؛ Dongqin Ma؛ Yingchun Duan* | ||
| Department of Obstetrics and Gynecology, Shanghai Pudong Hospital of Fudan University, Pudong, Shanghai-201399, China | ||
| چکیده | ||
| Objective(s): LOXL2, known as Lysyl oxidase-like 2, is classified as a lysyl oxidase (LOX) family member. However, its role and mechanism in endometrial cancer (EC) are unknown. Therefore, we aimed to investigate the potential role and mechanism of LOXL2 in EC. Materials and Methods: The levels of LOXL2 expression in EC tissues and normal adjacent tissues were evaluated by immunohistochemically (IHC) labeling. Following the dye application, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Transwell methodologies were executed to evaluate the effects of LOXL2 inhibition and up-regulation on the growth, programmed cell death, migration, and susceptibility to iron-dependent cell death of EC. Moreover, protein analysis through Western blotting and gene expression analysis using Real-time quantitative PCR (RT-qPCR) was employed to measure the levels of pertinent biomarkers. Results: LOXL2 is highly expressed in both EC tissues and serum in vivo. Silencing LOXL2 reduced EC cell proliferation and migration while increasing apoptosis in vitro. LOXL2 silencing increased the ferroptosis-related proteins Solute Carrier Family 7 Member 11 (SLC7A11) and Ferritin Heavy Chain 1 (FTH1) while decreasing Glutathione Peroxidase 4 (GPX4) (both, P<0.001). Additionally, LOXL2 silencing reduced the p-PI3K and p-Akt protein expression, while LOXL2 overexpression (OE-LOXL2) elevated the p-PI3K and p-Akt protein expression (both, P<0.001). Additionally, LOXL2 silencing increases SLC7A11 and FTH1 while decreasing GPX4 (both P<0.001). LOXL2 overexpression has the opposite effect. However, the LY294002 inhibitor restores SLC7A11 and FTH1 expression while decreasing GPX4 (P<0.001). Conclusion: Our research demonstrated that LOXL2 might protect EC via phosphorylation by activating the PI3K/AKT pathway. | ||
| کلیدواژهها | ||
| Apoptosis؛ Cell proliferation؛ Endometrial neoplasms؛ LOXL2 protein؛ Phosphorylation | ||
| مراجع | ||
|
1. Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med 2020; 383: 2053-2064. 2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505. 3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33. 4. Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecol Oncol 2021; 162: 226-234. 5. Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma. Annu Rev Pathol 2019; 14: 339-367. 6. Chen X, Kang R, Kroemer G, Tang, D. Ferroptosis in infection, inflammation, and immunity. J Exp Med 2021; 218: e20210518-20210532. 7. Hoy AJ, Nagarajan SR, Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer 2021; 21: 753-766. 8. Xiong Y, Xiao C, Li Z, Yang X. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem Soc Rev 2021; 50: 6013-6041. 9. Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 2022; 22: 381-396. 10. Wang H, Peng S, Cai J, Bao S. Silencing of PTPN18 induced ferroptosis in endometrial cancer cells through P-P38-mediated GPX4/xCT down-regulation. Cancer Manag Res 2021; 13: 1757-1765. 11. Jiang P, Yang F, Zou C, Bao T, Wu M, Yang D, et al. The construction and analysis of a ferroptosis-related gene prognostic signature for pancreatic cancer. Aging 2021; 13: 10396-10414. 12. Lin CC, Yang WH, Lin YT, Tang X, Chen PH, Ding CKC, et al. DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the hippo pathway. Oncogene 2021; 40: 2018-2034. 13. López-Janeiro Á, Ruz-Caracuel I, Ramón-Patino JL, De Los Ríos V, Villalba Esparza M, Berjón A, et al. Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. Cancers 2021; 13: 794-809. 14. Yang L, Tian S, Chen Y, Miao C, Zhao Y, Wang R, et al. Ferroptosis-related gene model to predict overall survival of ovarian carcinoma. J Oncol 2021; 2021: 1-14. 15. Yuan Y, Cao W, Zhou H, Qian H, Wang H. CLTRN, regulated by nrf1/ran/dld protein complex, enhances radiation sensitivity of hepatocellular carcinoma cells through ferroptosis pathway. Int J Radiat Oncol Biol Phys 2021; 110: 859-871. 16. Gao Z, Deng G, Li Y, Huang H, Sun X, Shi H, et al. Actinidia chinensis planch prevents proliferation and migration of gastric cancer associated with apoptosis, ferroptosis activation and mesenchymal phenotype suppression. Biomed Pharmacother 2020; 126: 110092-110101. 17. Vallet SD, Ricard-Blum S. Lysyl oxidases: From enzyme activity to extracellular matrix cross-links. Essays Biochem 2019; 63: 349-364. 18. Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis. Hepatology 2020; 72: 729-741. 19. Ferreira S, Saraiva N, Rijo P, Fernandes AS. LOXL2 inhibitors and breast cancer progression. Antioxid (Basel) 2021; 10: 312-327. 20. Matsuoka K, Bakiri L, Wolf LI, Linder M, Mikels-Vigdal A, Patiño-García A, et al. Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res 2020; 30: 885-901. 21. Luo F, Lu FT, Cao JX, Ma WJ, Xia ZF, Zhan JH, et al. HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer. Cancer Lett 2022; 531: 39-56. 22. Alonso-Nocelo M, Ruiz-Cañas L, Sancho P, Görgülü K, Alcalá S, Pedrero C, et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut 2022; 72: 345-359. 23. Cui X, Wang G, Shen W, Huang Z, He H, Cui L. Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer. Oncol Rep 2018; 40: 932-942. 24. Nguyen EV, Pereira BA, Lawrence MG, Ma X, Rebello RJ, Chan H, et al. Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment. Mol Cell Proteom 2019; 18: 1410- 1427. 25. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 2018; 15: 273-291. 26. Chen M, Choi S, Wen T, Chen C, Thapa N, Lee JH, et al. A p53-phosphoinositide signalosome regulates nuclear AKT activation. Nat Cell Biol 2022; 24: 1099-1113. 27. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 2020; 20: 74-88. 28. Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol 2019; 59: 125-32. 29. Chen D. Histological staining and its methods. J Interdiscip Histopathol 2022; 10: 1-2. 30. Zhang X, Tian B, Cong X, Ning Z. Corilagin inhibits angiotensin II-induced atrial fibrosis and fibrillation in mice through the PI3K-Akt pathway. Iran J Basic Med Sci 2024; 27: 717-724. 31. Jia N, Wang J, Li Q, Tao X, Chang K, Hua K, et al. DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer. Oncotarget. 2016; 7: 84785-84797. 32. Zhu X, Zhang X, Gu W, Zhao H, Hao S, Ning Z. ANGPTL4 suppresses the profibrogenic functions of atrial fibroblasts induced by angiotensin II by up-regulating PPARγ. Iran J Basic Med Sci 2023; 26: 587-593. 33. Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects astragaloside IV. Fundam Clin Pharmacol 2017; 31: 17-36. 34. Wen B, Xu LY, Li EM. LOXL2 in cancer: Regulation, downstream effectors and novel roles. Biochim Biophys Acta Rev Cancer 2020; 1874: 188435. 35. Mahjour F, Dambal V, Shrestha N, Singh V, Noonan V, Kantarci A, et al. Mechanism for oral tumor cell lysyl oxidase like-2 in cancer development: Synergy with PDGF-AB. Oncogenesis 2019; 8: 34-50. 36. Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014; 43: 1430-1438. 37. Fu Q, Bai Y, Liu Y, Zhou J, Zheng Y. The serum level and significance of lysyl oxidase-like 2 in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2018; 37: 193-198. 38. Zhao Y, Tang K, Tianbao X, Wang J, Yang J, Li D. Increased serum lysyl oxidase- like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation. Biosci Rep 2017; 37: BSR20171332-20171339. 39. Ruiz LA, Báez-Vega PM, Ruiz A, Peterse DP, Monteiro JB, Bracero N, et al. Dysregulation of lysyl oxidase expression in lesions and endometrium of women with endometriosis. Reprod Sci 2015; 22: 1496-1508. 40. Wu S, Xing X, Wang Y, Zhang X, Li M, Wang M, et al. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism. Eur J Cancer 2021; 147: 63-73. | ||
|
آمار تعداد مشاهده مقاله: 493 تعداد دریافت فایل اصل مقاله: 2,563 |
||